Ventria Bioscience Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ventria Bioscience Inc.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Pharmaceuticals, and Medical Devices – and then categorized by type –Acquisition, Alliance, or Financing.
As companies flurried to clinch deals by the end of the year, a number of significant agreements were signed or completed last December.
During the second quarter of 2011, 57 medical device companies brought in a total of $1.7 billion in financings. The M&A activity reached $28.8 billion, unusually high due to Johnson & Johnson's $21.7 billion takeover of orthopedic device maker Synthes. VC funding represented $76 million or 43% of the second quarter's in vitro diagnostics/research financing aggregate of $177 million. A hefty $4.1 billion was spent on 11 in vitro diagnostic/research M&A transactions, the largest being Thermo Fisher's $3.5 billion buy of Swedish genetics testing firm Phadia AB.
- Large Molecule
- Synthesis Technologies, Production Processes